Skip to main content
. Author manuscript; available in PMC: 2013 Aug 7.
Published in final edited form as: Adv Exp Med Biol. 2010;661:419–434. doi: 10.1007/978-1-60761-500-2_27

Fig. 27.2.

Fig. 27.2

Effect of sorafenib on hemodynamic measurements. (a, b) PA and RV systolic pressures, respectively, obtained in Dahl SS rodents at 3.5-week exposure to normoxia (n = 7), hypoxia/SU5416 (H-SU5416, n = 5), or hypoxia/SU5416/sorafenib treatments (H-SU-Sor, n = 5). (c) RV hypertrophy (RVH) measurements across all of the tested conditions represented by the ratio of RV mass divided by the sum of the mass of left ventricle (LV) plus septum (LV + septum). *p < 0.01, **p < 0.001